Company:  OREXIGEN THERAPEUTICS, IN ... (OREX)
Form Type:  8-K
Filing Date:  9/27/2011 
CIK:  0001382911 
Address:  3344 N. TORREY PINES CT.
SUITE 200
 
City, State, Zip:  LA JOLLA, California 92037 
Telephone:  (858) 875-8600 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$4.76  
Change: 
-0.17 (-3.45%)  
Trade Time: 
04:00 PM EST  
Market Cap: 
$596.05M
Trade OREX now with

Description of Business
Orexigen® Therapeutics, Inc. ("Orexigen," "we," "our" and "us") is a biopharmaceutical company focused on the treatment of obesity. Our product, Contrave®, was approved in the United States by the U.S. Food and Drug Administration, or FDA, in September 2014 as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index, or BMI, of 30 kg/m2 or greater (obese), or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia). In October 2013, we submitted an application for marketing authorization with the European Medicines Agency, or EMA, for Contrave under the name Mysimba(TM).
Register and access this filing in:     
  FORM 8-K
    SECTION 7 REGULATION FD
      Item 7.01. Regulation FD Disclosure.
    SECTION 9 FINANCIAL STATEMENTS AND EXHIBITS
      Item 9.01. Financial Statements and Exhibits.
    SIGNATURES
    EXHIBIT INDEX
  EXHIBIT 99.1